Valuation: LB Pharmaceuticals Inc

Market Cap 1.28B 1.15B 1.06B 961M 1.79B 122B 1.82B 12.68B 5.05B 63.73B 4.8B 4.7B 202B P/E 2026 *
-6.94x
P/E 2027 * -7.52x
Enterprise Value 899M 807M 746M 676M 1.26B 85.66B 1.28B 8.92B 3.55B 44.83B 3.38B 3.3B 142B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.76%
Yield 2026 *
-
Yield 2027 * -
1 day+0.48%
1 week+1.53%
Current month+3.78%
1 month+5.12%
3 months+14.00%
6 months+26.93%
Current year+78.93%
1 week 38.26
Extreme 38.26
41.58
1 month 33.13
Extreme 33.13
41.58
Current year 18.43
Extreme 18.43
50.16
1 year 14.32
Extreme 14.3166
50.16
3 years 13.36
Extreme 13.36
50.16
5 years 13.36
Extreme 13.36
50.16
10 years 13.36
Extreme 13.36
50.16
Manager TitleAgeSince
Chief Executive Officer 53 19/11/2024
Director of Finance/CFO 52 02/09/2026
Chief Tech/Sci/R&D Officer 54 14/09/2026
Director TitleAgeSince
Director/Board Member 76 01/07/2019
Director/Board Member 53 01/08/2023
Director/Board Member 53 19/11/2024
Date Insider Type Main position Quantity % Market Cap. Importance
9/10/26 Free

Chief Financial Officer

200,000 0.8911%
9/10/26 Free

Chief Technology Officer

200,000 0.8911%
30/7/26
Deep Track Capital LP
BuyCompany 286,205 0.8872%
Change 5-day change 1-year change 3-year change Capi.($)
+0.48%+1.53%+140.37% - 1.28B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.76%+0.87%+27.92%+57.51% 44.75B
+2.00%-3.39%+17.83%+100.08% 41.62B
+1.34%-2.86%+224.43%+928.45% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.13%-0.71%+60.97%+162.98% 38.17B
Weighted average by Cap. +3.20%-0.30%+47.90%+161.58%

Financials

2026 *2027 *
Net sales - -
Net income -178M -160M -148M -134M -250M -16.97B -253M -1.77B -704M -8.88B -669M -654M -28.19B -201M -180M -167M -151M -282M -19.15B -286M -1.99B -794M -10.02B -755M -739M -31.82B
Net Debt -379M -340M -315M -285M -532M -36.12B -539M -3.76B -1.5B -18.9B -1.42B -1.39B -60.01B -479M -430M -397M -360M -673M -45.64B -681M -4.75B -1.89B -23.88B -1.8B -1.76B -75.82B
Projected Income Statement - Annual - LB Pharmaceuticals Inc
Logo LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Employees
49
Date Price Change Volume
29/10/26 USD 39.83 +0.48% 201,178
27/10/26 USD 39.64 +0.76% 236,345
26/10/26 USD 39.34 +1.58% 275,975
23/10/26 USD 38.73 -1.75% 188,569
22/10/26 USD 39.42 +0.48% 230,854
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - LB Pharmaceuticals Inc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
39.64USD
Average target price
58.00USD
Spread / Average Target
+46.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - LB Pharmaceuticals Inc
  1. Stock Market
  2. Stocks
  3. LBRX Stock